Table 3.
Overall survival analysis stratified by estrogen receptor status/molecular typing in primary and metastatic sites (multivariable model).
| OS (time since the primary tumor prognosis) | No. of patients | No. of deaths | Adjusted HR* 95% CI | p-value |
|---|---|---|---|---|
| ER status | ||||
| Primary positive/metastasis positive | 134 | 47 | 1.000 (reference) | |
| Primary positive/metastasis negative | 35 | 18 | 2.245 (1.292–3.899) | 0.004 |
| Primary negative/metastasis positive | 16 | 7 | 0.905 (0.403–2.032) | 0.808 |
| Primary negative/metastasis negative | 78 | 54 | 4.640 (3.081–6.989) | p < 0.001 |
| Primary positive/metastasis positive | 134 | 47 | 0.284 (0.150–0.540) | p < 0.001 |
| Primary positive/metastasis negative | 35 | 18 | 0.379 (.0188–0.764) | 0.007 |
| Primary negative/metastasis positive | 16 | 7 | 0.366 (0.151–0.888) | 0.026 |
| Primary negative/metastasis negative | 78 | 54 | 1.000 (reference) | |
| OS (time since the primary tumor prognosis) | No. of patients | No. of death | Adjusted HR† 95% CI | p-value |
| Molecular typing conversion | ||||
| ER (+)/HER2 (+/−) to ER (+)/HER2 (+/−) | 136 | 49 | 1.000 (reference) | |
| ER (+)/HER2 (+/−) to ER (−)/HER2 (+/−) | 35 | 18 | 2.199 (1.343–3.965) | 0.005 |
| ER (−)/HER2 (−) to ER (+)/HER2 (+/−) | 10 | 6 | 1.436 (0.603–3.422) | 0.414 |
| ER (−)/HER2 (−) to ER (−)/HER2 (−) | 29 | 23 | 5.475 (3.277–9.146) | p < 0.001 |
| ER (+)/HER2 (+/−) to ER (+)/HER2 (+/−) | 136 | 49 | 0.183 (0.109–0.305) | p < 0.001 |
| ER (+)/HER2 (+/−) to ER (−)/HER2 (+/−) | 35 | 18 | 0.402 (0.213–0.756) | 0.007 |
| ER (−)/HER2 (−) to ER (+)/HER2 (+/−) | 10 | 6 | 0.262 (0.103 to 0.668) | 0.005 |
| ER (−)/HER2 (−) to ER (−)/HER2 (−) | 29 | 23 | 1.000 (reference) | |
After adjustment for age of primary tumor diagnosis (continuous), age of first metastasis diagnosis (continuous), PR status in primary and metastatic sites, site of metastasis (local and distant metastasis), tumor size, lymph node metastasis, adjuvant therapy (radiotherapy, endocrine, chemotherapy, and anti-HER2 therapy), and first-line therapy (endocrine, chemotherapy, and anti-HER2 therapy).
After adjustment for age of primary tumor diagnosis (continuous), age of first metastasis diagnosis (continuous), site of metastasis (local and distant metastasis), tumor size, lymph node metastasis, adjuvant therapy (radiotherapy, endocrine, chemotherapy, and anti-HER2 therapy), and first-line therapy (endocrine, chemotherapy, and anti-HER2 therapy).
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; OS, overall survival.